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Abstract
Retinitis pigmentosa (RP) is an inherited retinal dystrophy caused by the loss of photoreceptors
and characterized by retinal pigment deposits visible on fundus examination. Prevalence of non
syndromic RP is approximately 1/4,000. The most common form of RP is a rod-cone dystrophy, in
which the first symptom is night blindness, followed by the progressive loss in the peripheral visual
field in daylight, and eventually leading to blindness after several decades. Some extreme cases may
have a rapid evolution over two decades or a slow progression that never leads to blindness. In
some cases, the clinical presentation is a cone-rod dystrophy, in which the decrease in visual acuity
predominates over the visual field loss. RP is usually non syndromic but there are also many
syndromic forms, the most frequent being Usher syndrome. To date, 45 causative genes/loci have
been identified in non syndromic RP (for the autosomal dominant, autosomal recessive, X-linked,
and digenic forms). Clinical diagnosis is based on the presence of night blindness and peripheral
visual field defects, lesions in the fundus, hypovolted electroretinogram traces, and progressive
worsening of these signs. Molecular diagnosis can be made for some genes, but is not usually
performed due to the tremendous genetic heterogeneity of the disease. Genetic counseling is
always advised. Currently, there is no therapy that stops the evolution of the disease or restores
the vision, so the visual prognosis is poor. The therapeutic approach is restricted to slowing down
the degenerative process by sunlight protection and vitaminotherapy, treating the complications
(cataract and macular edema), and helping patients to cope with the social and psychological impact
of blindness. However, new therapeutic strategies are emerging from intensive research (gene
therapy, neuroprotection, retinal prosthesis).
Disease name
Retinitis pigmentosa
Definition
Retinitis pigmentosa (RP) belongs to the group of pig-
mentary retinopathies, a generic name that covers all reti-
nal dystrophies presented with a loss of photoreceptors
and retinal pigment deposits. RP is a retinal degenerative
disease characterized by pigment deposits predominant in
the peripheral retina and by a relative sparing of the cen-
tral retina. In most of the cases of RP, there is a primary
degeneration of the photoreceptor rods, with secondary
degeneration of cones. Thus, the typical RP is also
described as a rod-cone dystrophy, photoreceptor rods
being more affected than cones. This sequence of photore-
ceptor involvement explains why patients initially present
with night blindness, and only in the later life would suf-
fer visual impairment in diurnal conditions.
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Diagnostic criteria
Functional signs
￿ Night blindness (nyctalopia) is the earliest symptom
￿ Photophobia appears later
￿ The visual acuity is preserved in early and mid stages
Visual field
￿ Patchy losses of peripheral vision evolving to
￿ Ring shape scotoma, and eventually
￿ Tunnel vision
Fundus
￿ Pigmentary deposits resembling bone spicules, initially
in peripheral retina
￿ Attenuation of the retinal vessels
￿ Waxy pallor of the optic disc
￿ Various degrees of retinal atrophy
Electroretinogram
￿ Dramatic diminution in a- and b-wave's amplitudes
￿ Scotopic system (rods) predominates over photopic
(cones) system
Epidemiology
Prevalence of non syndromic RP is approximately 1/4,000
[1-5].
Clinical description
Non syndromic retinitis pigmentosa
Typical form
RP is a long lasting disease that usually evolves over sev-
eral decades. However, there are extreme cases with a
rapid evolution over two decades or a slow progression
that never leads to blindness. The disease course can be
conveniently divided into three stages.
In the early stage, night blindness is the main symptom.
It may be present from the first years of life or may appear
during the second decade, or even later. Mild night blind-
ness is often ignored by the patients and becomes appar-
ent in the teen age, at evening parties. At this stage, there
may be peripheral visual field defects in dim light. How-
ever, these defects do not exist or are minimal in day light,
thus patients have normal life habits and the disease may
appear stable. Diagnosis is difficult to establish at this
stage, particularly when there is no familial history (about
half of the cases). Visual acuity is normal or subnormal.
Fundus examination (Figure 1) may seem normal, as
bone spicule-shaped pigment deposits are not present or
rare. Morevover, the attenuation of retinal arterioles is
modest and the optic disc is normal. The visual field test
reveals scotomas only in scotopic conditions, while the
test is usually done in mesopic conditions. Color vision is
normal. The electroretinogram (ERG) is the key test. In
most cases, it shows a decreased amplitude of the b-wave
that predominates in scotopic conditions. However, ERG
may appear normal when the retina is only partially
affected, though the decrease in maximum ERG ampli-
tude.
In the mid stage, the clinical picture is complete. Night
blindness is obvious, with difficulties to drive during the
night, and to walk at evening and in dark staircases.
Patients become aware of the loss in the peripheral visual
field in day light conditions through stereotypic situa-
tions: while driving, they do not see pedestrians or side-
coming cars, they miss hands in handshaking and fre-
quently step into various objects. Consequently, patients
adapt themselves by avoiding night driving and circula-
tion in unfamiliar places. Dyschromatopsia to pale colors
(particularly blue and yellows hues) is often present. In
addition, patients become photophobic, especially in
presence of diffuse light (white cloudy weather). This
leads to reading difficulties, with a narrow window
between insufficient and too bright light. Difficulties with
reading are due also to decreased visual acuity, partly
because of macular involvement (macular edema or mild
foveomacular atrophy) and subcortical posterior cataract.
Fundus examination (Figure 2) reveals the presence of
bone spicule-shaped pigment deposits in the mid periph-
ery, along with atrophy of the retina. Narrowing of the ret-
inal vessels is evident and the optic disc is moderately
pale. In contrast, the extreme periphery and the macular
region appear relatively spared, although mild macular
Fundus of patient with retinitis pigmentosa, early stage Figure 1
Fundus of patient with retinitis pigmentosa, early stage.Orphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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involvement is frequent. The ERG is usually unrecordable
in scotopic conditions (rods) and the cone responses (30-
Hz flickers, bright light) are markedly hypovolted. Pheno-
typic features of the disease should be carefully registered
to guide towards mutation searches. At this stage, evalua-
tion of the rate of the disease progression, based on sev-
eral year-to-year examinations (visual acuity, ERG and
most importantly visual field testing), is mandatory.
Indeed, visual field testing shows mild periphery scoto-
mas that tend to enlarge towards extreme periphery and
macular area. Cataract, which usually blurs the optic
center, should be removed even when there is macular
involvement.
In the end stage, patients can no longer move autono-
mously, as a result of peripheral vision loss (classical tun-
nel vision), with few degrees of remaining visual field
around the fixation point. Reading is difficult and magni-
fying glasses are necessary. Photophobia is intense. Fun-
dus examination (Figure 3) reveals widespread pigment
deposits reaching the macular area. Vessels are thin and
the optic disc has a waxy pallor. Fluorescein angiography
detects chorioretinal atrophy in the periphery and also in
the foveomacular area. The ERG is unrecordable. Even at
this stage, the disease progression remains slow, with
patients being able to read short passages for years, while
being totally incapable to move. However, reading
becomes impossible when the central visual field van-
ishes. Usually, patients continue to perceive light, often in
the peripheral visual field.
Clinical forms
There are many forms of non syndromic RP that can be
classified on the basis of several criteria:
• Age of onset
Early onset RP is diagnosed when symptoms of mid stage
RP are already present at the age of two years. These forms
may be difficult to distinguish from Leber's congenital
amaurosis (LCA) in which a severe visual impairment is
present from birth or at least in the first year of life. In fact,
mutations in RPE65, CRB1, CRX and TULP1 genes cause
retinal dystrophies that are diagnosed as either LCA or RP,
depending on the age of onset [6].
Alternatively, late onset RP is diagnosed when symptoms
of early stage RP are apparently beginning at or after mid
life. One possibility is that moderate night blindness from
infancy is ignored by the patient and slowly worsens to
the point where it becomes clinically apparent. Another
possibility is RP truly to begin late. In this case, one must
search for a non genetic cause of similar phenotype such
as ocular trauma or inflammation/infection, paraneopla-
sic syndromes, association with a spinocerebellar ataxia,
particularly if there is a rapid evolution of the symptoms.
Fundus appearance
￿ Absence or scarcity of pigment deposits may occur. This
is frequent in myopia because of the retinal pigment atro-
phy linked to this condition. In other cases, the amount of
pigment deposits may vary and does not necessarily
reflect the severity of the disease.
￿ Localization of the lesions. There are regional or secto-
rial forms in which only one or two quadrants are affected
(RHO, PRPF31 mutations). The lesions may also be local-
Fundus of patient with retinitis pigmentosa, end stage Figure 3
Fundus of patient with retinitis pigmentosa, end stage (Pig-
ment deposits are present all over the retina. Retinal vessels 
are very thin and optic disc is pale.)
Fundus of patient with retinitis pigmentosa, mid stage Figure 2
Fundus of patient with retinitis pigmentosa, mid stage (Bone 
spicule-shaped pigment deposits are present in the mid 
periphery along with retinal atrophy, while the macula is pre-
served although with a peripheral ring of depigmentation. 
Retinal vessels are attenuated.)Orphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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ized as a ring around the macula (pericentral), the optic
disc (parapapillary) or predominantly along retinal veins
(paraveinous). In some cases, there is paraarteriolar reti-
nal pigment epithelium preservation (CRB1 mutations).
Finally, there are rare cases of unilateral RP for which a
local cause (trauma) should be actively searched.
￿ Other lesions. White dots or whitish spots can be
present as in retinitis punctata albescens (RLBP1 muta-
tions). Macular atrophy can be quite prominent from the
mid stage of the disease (RDS and CRX mutations).
Mode of inheritance
￿ Autosomal dominant forms are usually the mildest
forms, with some cases starting after the age of 50,
although severe disease can also appear. Variations in
penetrance are frequent, particularly in case of PAP1,
PRPF31 and RP1 mutations. In genetic counseling, one
should always suspect autosomal dominance in appar-
ently sporadic mild cases, especially when ascendants
have not been thoroughly examined or are unknown.
￿ Autosomal recessive forms start typically during the first
decade, although some mild forms can be encountered.
￿ X-linked forms also start early and are frequently associ-
ated with myopia. Although transmission is recessive in
most cases, there are some families in which dominant
inheritance with affected females is found.
￿ Digenic form: rare cases have been described in which
heterozygous mutations in ROM1 in combination with
heterozygous mutations in RDS cause digenic RP. These
forms are inherited in a pseudo-dominant pattern (1/4
risk).
Syndromic retinitis pigmentosa
Many syndromes associate with various types of pigmen-
tary retinopathies.
Frequent syndromes
￿ Usher syndrome is the most frequent syndromic form
in which typical RP is associated with neurosensory deaf-
ness. About 14% of all RP cases are, in fact, Usher syn-
drome [7]. Deafness, generally congenital and stable, may
be profound (type 1) or moderate/medium (type 2). In
some cases deafness occurs during the first decade and
worsens progressively (type 3). Mutations in at least 11
genes are responsible for Usher syndrome (for review see
[8]).
￿  Bardet Biedl syndrome (BBS) is less frequent than
Usher syndrome (prevalence 1/150,000 [9]). The pheno-
type is characteristic and associates RP (often of cone-rod
dystrophy type) with obesity already present in child-
hood, mental retardation or mild psychomotor delay,
post axial polydactyly, hypogenitalism and renal abnor-
malities that lead to renal failure. BBS is due to mutations
in at least 11 genes [10,11], with cases of triallelic digenic
inheritance [12]. The rare Alstrôm syndrome (due to
ALMS1 gene mutation) resembles BBS and presents with
deafness, diabetes mellitus and acanthosis nigricans.
Less frequent syndromes
Renal abnormalities
￿ Senior Loken syndrome (SLS) associates an usually
severe RP (sometimes diagnosed as LCA) with neph-
ronophtisis (renal atrophy frequently evolving towards
renal failure requiring transplantation), or sometimes a
milder RP that is discovered later in life. At least four genes
(NPHP1, NPHP3-5) encoding nephrocystins are involved
in this disease [13].
￿ Alport syndrome: deafness and progressive nephritis
are associated with yellow flecks around the macula,
rather than with an authentic RP.
Dysmorphic syndromes
￿ Cohen syndrome associates RP to a particular facial dys-
morphism (prominent upper incisors) with short stature,
mental retardation, long and narrow hands, and neutro-
penia. One causative gene (COH1) that encodes a protein
involved in vesicular trafficking, is related to this syn-
drome [14].
￿ Jeune syndrome associates RP with a thoracic hypopla-
sia, brachydactyly and chronic nephritis. One locus has
been identified (asphyxiating thoracic dystrophy, ATD).
￿ Cockayne syndrome is characterized by dwarfism, pro-
geria, mental retardation, and retinopathy with fine gran-
ular spots.
Metabolic diseases
￿  Methylmalonic aciduria with homocystinuria is
caused by genetic defects in enzymes that metabolize vita-
min B12. Rare cases present with macular atrophy, salt-
and-pepper retinopathy, and vascular attenuation.
￿ Abetalipoproteinemia (Bassen Korntzweig disease) is
characterized by progressive ataxia, steatorrhea, reduction
of plasma lipids and pigmentary retinopathy that resem-
bles retinitis punctata albescens in some cases.
￿  Bietti's disease shows characteristic microcrystalline
deposits in fundus and cornea. Patients undergo progres-
sive RP evolving towards chorioretinal atrophy. The caus-
ative gene, encoding a form of cytochrome P450
(CYP4V2), has been recently discovered [15].Orphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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￿ Cystinosis presents with typical crystal deposits in the
cornea and pigmentary retinopathy in a highly photopho-
bic patients with short stature. Accumulation of cystine in
other body parts leads to hypothyroidism, diabetes melli-
tus, and renal failure. The causative gene (CTNS) encodes
a protein (cystinosin) involved in the lysosomal trans-
membrane transport of cystein [16].
￿ Mucopolysaccharidoses are characterized by facial and
bony changes, mental retardation and corneal clouding.
Only types I, II and III show pigmentary retinopathy.
￿ Zellweger (cerebro-hepato-renal) syndrome.
￿ Hyperoxaluria type I with retinal atrophy in spots.
￿ Neonatal adrenoleukodystrophy with leopard spots
in fundus.
￿ Infantile Refsum disease (caused by mutation in the
PEX1, PEX2 or PEX26 genes) presents with elevated phy-
tanic acid and pigmentary retinopathy with characteristic
prominent macular involvement.
￿ Adult Refsum disease caused by mutation in the gene
encoding phytanoyl-CoA hydroxylase (PAHX or PHYH)
or the gene encoding peroxin-7 (PEX7) presents with
highly elevated phytanic acid, anosmia, deafness, and RP.
￿  Peroxisomal disorders other than Refsum disease:
except for the rhizomelic chondrodysplasia punctata, all
children with disorders of peroxisomal assembly who sur-
vive long enough develop pigmentary retinopathy.
Neurological diseases
￿ Neuronal ceroid lipofuscinosis (also called Batten dis-
ease or amaurotic idiocies), associates mental retardation,
seizures, ataxia and retinal degeneration. The retinal dis-
ease starts with macular involvement (red-cherry spot)
and later spreads to peripheral retina. The protein,
encoded by CLN3, is found in the lysosomes and in syn-
apses [17].
￿ Joubert syndrome (JBTS) is a phenotypically heteroge-
nous syndrome that associates various central nervous
system (CNS) developmental abnormalities including the
so-called "molar tooth sign", cerebellar vermis hypoplasia
and cerebral cortex defects, with renal cysts, and pigmen-
tary retinopathy. There are overlaps with Senior Loken
syndrome, as NPHP1 is a causative factor in about 2% of
JBTS4. Another causative gene, AHI1, has been recently
discovered in the JBTS3 form [18,19]. There are two other
loci (JBTS1-2).
￿ Autosomal dominant cerebellar ataxia type II (SCA7)
shows a retinal disease, which often begins with a granu-
lar macula and then spreads out to the whole retina. It is
due to trinucleotide expansions in the transcription factor
ataxin-7 and anticipation effect is found [20].
￿ Myotonic dystrophy shows cataract and sometimes
pigmentary retinopathy.
￿ Hallervorden-Spatz syndrome shows progressive dys-
arthria and dementia, iron deposition, and flecked type
retinopathy with bull's eye maculopathy.
Etiology
Causative genes
Non syndromic
RP are genetic disorders inherited as mendelian traits in
most cases. Except for mutation in a few genes that can
cause both autosomal dominant and recessive forms of
RP (NRL, RP1 and, exceptionally, RHO), most genes
involved in the disease are linked to only one form of
inheritance. There are also some rare RP cases due to mito-
chondrial DNA mutations [21] and to digenic diallelic
inheritance involving RDS and ROM1 genes [22]. Unipa-
rental isodisomy and incomplete penetrance have also
been described (reviewed in [23]).
In 1990, the first gene involved in RP, Rhodopsin, has been
identified [24]. It encodes the rod visual pigment. Since
then, it has been established that mutations in many
genes may cause RP [25]. To date, 45 known genes/loci
have been identified in non syndromic RP, including 15 for
autosomal dominant- (14 cloned, one mapped), 24 for
autosomal recessive- (18 cloned, six mapped), five for X-
linked- inheritance (two cloned, three mapped), and one,
ROM1, which has been found mutated only in digenism
with RDS. It has been estimated that the cloned genes
account for about 50% of dominant RP, 40% of recessive
RP and approximately 80% of X-linked RP, indicating that
many genes remain to be identified [26].
The gene products localize in rods (sometimes in rods and
cones), being involved in various metabolic pathways.
They include proteins of the rod visual transduction (rho-
dopsin, α and β subunits of the rod phosphodiesterase, α
and β subunits of the rod cGMP gated channel, arrestin,
guanylate cyclase activating protein 1B), cytoskeleton pro-
teins (peripherin/RDS, ROM1, fascin 2), proteins presum-
ably involved in trafficking (RPGR, RP1, RP2, prominin-
like 1), in photoreceptor differentiation (NRL, NR2E3,
CRX), in mRNA splicing (PRPC8, HPRP3, PRPF31, PAP1),
in the composition of extracellular matrices (USH2A),
and in lipid (ABCA4, CERKL), nucleotide (IMPDH1) or
other (TULP1, CRB1, MITS2, CA4, SEMA4A) metabolic
pathways. In addition, RP is also caused by mutations ofOrphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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genes expressed in the photoreceptor supporting tissue,
i.e. the retinal pigment epithelium (RPE), the encoded
proteins being involved in the retinol metabolism (the
retinol isomerase RPE65, the 11-cis retinoid transporter
CRALBP, the lecithin retinol acyl transferase LRAT, RGR)
or in the phagocytosis of the photoreceptor outer seg-
ments (cMERTK).
Specificities of photoreceptors
The genetic heterogeneity of RP is difficult to correlate
with the fairly homogeneous phenotype of the disease.
Photoreceptors, and particularly rods, may require a
highly regulated environment to function properly and
any alteration of this environment may render these cells
prone to apoptosis, causing loss of rods and cones. Rods
have a very elongated outer segment that contains several
hundreds of membrane discs in which visual transduction
occurs. Discs contain huge amounts of visual transduction
proteins, particularly rhodopsin (~4 × 107 molecules per
rod) and cytoskeleton proteins. Discs of the apex of the
rod outer segment are phagocytosed daily by the retinal
pigment epithelium (RPE), and this phenomenon is com-
pensated by a daily boost of disc synthesis at the base of
the outer segment. This requires an intense activity of
mRNA and protein synthesis, as well as an important pro-
tein trafficking from the rod inner segment, through the
connecting cilium, to the rod outer segment. This cellular
activity generates an important energy consumption,
requiring high content of mitochondria and oxygen, and
mechanisms to protect the cell against the oxidative stress.
Possible common pathways to photoreceptor cell death
Loss of the rod outer segment may be caused by mutations
that lead to its destabilization (mutations in cytoskeleton
or trafficking proteins). This would considerably shorten
the photoreceptor layer and expose the photoreceptor cell
body to high pressure levels in oxygen, hence oxygen tox-
icity. Mutations that lead to diminution in the ability to
respond to high demand of energy or mRNA/protein syn-
thesis may somewhat destabilize the outer segment. Other
mechanisms that may be involved are calcium toxicity or
metabolic exhaustion by permanent opening of the
cGMP-gated channel, due to defective visual transduction
proteins, or, conversely, due to low calcium when visual
transduction permanently activated [27]. Finally, altera-
tions in critical RPE functions, such as disc phagocytosis
or retinol metabolism, may also deregulate the fine bal-
ance of photoreceptor metabolism.
Research process
Identification of the causative genes is a necessary step
towards the understanding of RP pathophysiology. With
the use of genetic databases, it can be reasonably assumed
that most genes responsible for autosomal dominant and
X-linked RP will be known within the next few years. This
will not be as straightforward in autosomal recessive RP
and some sporadic cases, as these forms seem to be asso-
ciated with an extreme genetic diversity. For each gene, we
then need to explore what causes the decrease in the visual
performance on the one hand, and how the mutated or
absent protein causes the loss in photoreceptor, on the
other hand. This implies the development of animal mod-
els and long lasting experiments based on cell and molec-
ular biology techniques. From this knowledge,
therapeutic trials are being conducted.
Diagnostic methods
Clinical diagnosis is based on the presence of night blind-
ness and peripheral visual field defects, lesions in fundus,
hypovolted ERG traces, and progressive worsening of
these signs. Full field ERG is the key test, particularly when
patients are asymptomatic and show normal fundus at
early stages of the disease or in autosomal dominant
forms with variable penetrance, since it is usually hypo-
volted before the appearance of clinical signs (night blind-
ness). It is important to ascertain the diagnosis by
repeating the examination one or two years after it has
been first established. Multifocal ERG and electrooculo-
gram are not essential to establish the diagnosis.
At present, a systematic molecular diagnosis is not rou-
tinely performed, due to the tremendous genetic heteroge-
neity of the disease. However, rapid and large-scale
mutation screening techniques are developing and several
laboratories perform search for mutations in the most fre-
quently involved genes, including:
￿ RPGR that accounts for at least 10% of all cases of non
syndromic RP, including 55% of X-linked RP and until
25% of sporadic RP. It is also involved in cases of X-linked
cone or macular dystrophies.
￿ RHO that accounts for 15 to 20% of dominant non syn-
dromic RP cases.
￿ USH2A may account for 1/3 to 1/2 of cases with Usher
syndrome and may be involved in at least 16% of cases
with recessive non syndromic RP [28].
In some instances, molecular diagnosis for certain genes is
performed by the laboratories that have discovered them.
The currently known genes responsible for RP account for
50–60% of the cases, and strategies to test in a short time
several dozen of genes for a single patient DNA are emerg-
ing [29,30].
Differential diagnosis
Leber's congenital amaurosis (LCA), which also belongs
to the group of pigmentary retinopathies, must be differ-Orphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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entiated from RP, although some genes are involved in
both LCA and RP. RP is also clearly different from the
macular dystrophies in which the extent of the lesions are
limited to the macula. Cone dystrophies, due to cone
degeneration while rods remain unaffected or only mod-
erately affected, must also be excluded, although some
genes cause either cone dystrophies or RP. Finally, cone-
rod dystrophies that are usually viewed as a subclass of RP
should be distinguished from typical RP (rod-cone dystro-
phy).
Various entities resemble RP:
Night blindness in non degenerative diseases
In these cases, in contrast to RP, the disease is not evolving
with time.
￿ Congenital stationary night blindness. In autosomal
forms, symptoms are limited to night blindness, while X-
linked forms are associated with a limited visual acuity.
￿ Fundus albipunctatus is a rare condition in which fine,
white deposits are visible in fundus. The fundus aspect is
similar to retinitis punctata albescens (see above), but
there is usually no signs of degeneration (narrowing of
retinal vessels, retinal atrophy), although some cases may
undergo macular degeneration [31].
￿ Vitamin A deprivation syndrome mimics the signs of RP
with night blindness and is associated with keratitis. If
vitamin A supplementation is given early, the symptoms
disappear but after a certain point the lesions become irre-
versible.
Non evolving pigmentary retinopathies
The aspect of the fundus is often that of salt-and-pepper
pigmentary retinopathy or deposits of pigment with vari-
ous shape, often dot-like.
￿ Congenital infections like rubella (salt-and-pepper
retinopathy) or syphilis (pseudo-retinitis pigmentosa or
leopard skin retinopathy).
￿ Carriers of X-linked disorders like choroideremia, ocular
albinism, RP. This helps to recognize carriers, in particular
for RP in which a yellowish reflex may be present in fun-
dus.
￿ Mitochondrial diseases like Kearns-Sayre syndrome
(ophthalmoplegia), although there may be progressive
degeneration of photoreceptors.
￿ Grouped congenital hypertrophy of the retinal pigment
epithelium with characteristic bear-like footprints in fun-
dus.
Choroidal dystrophies
In all cases there is a marked atrophy of the choriocapilla-
ris that is readily diagnosed by the absence of fluorescence
in fluorescein angiography.
￿ Choroideremia, an X-linked disorder, due to mutations
in CHM encoding the Rab Escort Protein 1 (REP1) and
accounting for about 2% of pigmentary retinopathies.
￿ Gyrate atrophy, a very rare autosomal recessive disorder,
due to deficiency in ornithine aminotransferase.
Vitreoretinopathies
In these conditions, the vitreous and inner layers of the
retina are also affected. Retinal detachment and retinal
vasculopathy are often present.
￿ Retinoschisis, in most cases the juvenile X-linked retin-
oschisis with typical spoke-wheel-like lesions in the fovea,
is due to mutations in XLRS1 encoding a protein involved
in the adhesion of retinal cells. End stage X-linked retino-
schisis are difficult to distinguish from RP because of the
macular degeneration and frequent pigmented lesions in
peripheral retina. There is also the autosomal recessive
Goldman Favre syndrome in which patients have night
blindness from infancy and show foveal retinoschisis in
fundus. It is the same disease as the Enhanced S-Cone Syn-
drome (ESCS) due to mutations in NR2E3, that presents
with characteristic whitish and secondarily round pig-
mented lesions in retinal periphery when evolved.
￿ Hereditary vitreoretinopathies, the most frequent ones
being several autosomal dominant conditions: familial
exudative vitreoretinopathy, Wagner disease and Stickler
syndrome.
￿ Inflammatory diseases of the eye, birdshot
choroidoretinopathy, serpiginous retinopathy, multifocal
placoid pigment epitheliopathy, sarcoidosis. The presen-
tation and fundus are clearly different from RP but there
may be a secondary degeneration mimicking RP.
Maculopathies
Large, extended maculopathies may be difficult to differ-
entiate from end stage RP.
￿ Stargardt disease, due to mutations in ABCA4. Null
mutations in this gene can also be responsible for authen-
tic RP.
￿ Cone dystrophies, in some cases presenting with a min-
imal rod involvement.
￿ Sorsby's disease, in extended cases.Orphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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Secondary pigmentary changes
Several diseases may lead to secondary RP with variable
disease course.
￿ Intoxication with various drugs including thioridazine
and chloroquine. Although chloroquine usually leads to
"bull's eye maculopathy", there are some cases of RP-like
pigmentary retinopathies that may continue to progress
even after discontinuation of the drug intake.
￿ Inflammation (pars planitis, Behcet disease, sarcoidosis,
subacute diffuse unilateral neuroretinitis) may rarely be
complicated with RP.
￿ Sequelae of severe gravidic toxemia, uveal effusion syn-
drome or trauma.
￿ Parasitic infections such as onchocercosis.
Genetic counseling
Once the diagnosis is made, patients should be informed
and familial surveys recommended. Genetic counseling is
always advised since all genetic forms can be encountered
in RP. A precise phenotypic diagnosis is always mandatory
and is particularly useful in the absence of familial history
or in sporadic cases.
Antenatal diagnosis
Prenatal diagnosis (amniocentesis or chorionic biopsy)
raises an ethical issue: whether the investigative risks asso-
ciated with these invasive prenatal procedures are justified
in a non life-threatening disease is questionable. Prenatal
diagnosis can be performed in families in which the
responsible gene has been identified, particularly in fami-
lies with early onset and severe RP.
Management including treatment
Currently, there is no therapy that stops the evolution of
pigmentary retinopathies or restores the vision. However,
there are several therapeutic strategies aimed at slowing
down the degenerating process, treating the complica-
tions and helping patients to cope with the social and psy-
chological impact of blindness.
Slowing down the degenerating process
Light protection
Clinical evidence and data from animal studies indicate
that some genetic types of pigmentary retinopathies are
partly light-dependent [32]. Thus, patients with pigmen-
tary retinopathies are recommended to wear dark glasses
outdoor. Wearing of yellow-orange spectacles minimizes
photophobia. Eyeshade and lateral protection help to
protect against dazzling side-coming light rays.
Vitaminotherapy
Vitamins A and E may protect the photoreceptors by
trophic and anti-oxidant effects, respectively. Previous
studies have demonstrated that long term (5–12 years)
vitamin A supplementation at doses of 15,000 units per
day slightly slowed down the loss in ERG amplitude,
while vitamin E at 400 units per day had adverse effects
[5]. However, the conclusions of this study were debated
[33], thus there is no consensus about the usefulness of
vitamin A treatment. If vitamin A supplementation is pro-
posed, levels of serum retinol (normal <3.49 μmol/l, i.e.
<1 mg/l) and triglyceridemia (normal <2.13 mmol/l, i.e.
<0.19 g/l) should regularly be checked, as well as liver
enzymes (aspartate aminotransferase, alanine ami-
notransferase and alkaline phosphatase) since vitamin A
storage occurs mainly in this organ. Vitamin A should not
be given to RP patients with mutations in ABCA4. In a
recent study, patients were given docosahexaenoic acid
(DHA) supplementation at 1200 mg/day, in addition to
vitamin A. It was shown that the course of the disease was
initially slowed down by the addition of DHA, but this
beneficial effect did not last over 2 years [34].
Treatments of complications
The most frequent complications are cataract and macular
edema.
Cataract
It is a posterior central subcapsular cataract with a clear
nucleus, which is usually present at mid stage in the evo-
lution of the disease. Although the cataract is not wide-
spread, its central position blurs the remaining central
visual field. Therefore, cataract provokes a sight restriction
and generates photophobia. Phacoemulsification with
implantation of intraocular lens is thus required.
Macular edema
Macular edema occurs frequently, causing a decrease in
the visual acuity. Acute episodes of macular edema may be
successfully treated with carboanhydrase inhibitors such
as acetazolamide sodium at a daily dose of 500 mg or less.
However, the macular edema in RP patients is most often
chronic and does not improve with this treatment [35].
Topical administration of dorzolamide is inefficient [36].
Inflammatory reactions
Mild inflammatory reactions occur frequently in the vitre-
ous and are often associated with macular edema, vascular
diffusion visible on fluorescein angiogram, and early cat-
aract. Although these reactions do not require a specific
treatment, some cases present with large exsudates in the
peripheral retina (pseudo Coats) that leads to retinal
detachment and rapid evolution towards blindness. This
latter complication has been found recurrently in RPOrphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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linked to CRB1 mutations [37]. Cryotherapy or laser treat-
ment are required for resorption of the exudates.
Others
Myopia associated with X-linked RP requires manage-
ment and routine examinations as for non RP patients.
Glaucoma is not associated with RP but the presence of
increased intraocular pressure in RP patients should be
cautiously checked in order to prevent more rapid deteri-
oration of the visual field.
Management of blind patients
Psychological help is often necessary at milestones in the
course of the disease: announcement, occurrence of mov-
ing difficulties and loss of reading. This support can be
provided by either professionals or supportive patients'
associations. Patients should be oriented towards institu-
tions that help them to rehabilitate (short- and medium-
stay stages and others [38] and to obtain new professional
skills.
Future treatments
Enormous efforts have been invested to identify the
involved genes, to unravel the underlying pathophysio-
logical mechanisms, and to find efficient treatments.
Search for new therapies follows several strategies, which
may be non exclusive. None of these future treatments is
currently operating in humans.
Treating the cause of the disease
• Gene therapy
This approach requires the implicated genes to be identi-
fied and therefore, the availability of efficient genotyping
methods. The strategy is relatively simple for RP due to
loss-of-function (usually recessively inherited). In this
case, one expect that the expression of the wild-type cDNA
in the appropriate cell (photoreceptor or RPE) will avoid
cell death. However, it is more complicated for RP due to
dominant negative pathogenic mechanisms in which the
expression of the mutated gene should be inhibited, by
use of ribozymes or siRNA for example. In the last 10
years, studies have been carried out in several animal
models. Although all showed a significant rescue of pho-
toreceptors, there was still progressing photoreceptor cell
death, which could be due to an inappropriate expression
level of the therapeutic gene and to an insufficient per-
centage of transduced photoreceptors. The most advanced
studies have been performed for LCA in a large animal
model (the Briard dog) in which the surgical administra-
tion in the subretinal space of AAV vectors carrying the
RPE65 cDNA allowed to restore vision in four month-old
dogs in USA [39,40] and in France [41]. Five years later,
the dog vision seems stable, although the very long-term
efficiency still remained to be ascertained. Promising
results have been obtained in a mouse model of X-linked
retinoschisis [42]. It is expected human trials in RPE65
patients to be carried out soon in the USA, UK, France,
and other countries.
• Pharmacological treatment
In those cases where some aspects of the pathophysiolog-
ical mechanism are known, pharmacological treatment
may be a good choice, as it offers the advantages of using
available drugs with known toxicity that can be modu-
lated. Pharmacological agents can compensate for a bio-
chemical defect, and enhance or inhibit the activity of
various effectors. Calcium-channel blockers have been
tried in several animal models of RP [43], yet with limited
success [44]. Another example is Stargardt disease in
which the use of visual cycle inhibitors has been shown to
slow down the toxic accumulation of lipofuscin in the
RPE in a mouse model [45,46]. Supply of 9-cis retinal has
been shown to restore the rod activity in a Rpe65-/- mouse
model of LCA [45]. NAD analogues supply in RP due to
IMPDH1 defects may also be efficient [48]. It might be
speculated that the alternative of pharmacological treat-
ments would be explored in more details in the future, as
the mechanisms of the various forms of RP will be pro-
gressively unraveled.
Coping with photoreceptor cell death
A general problem with the treatment of the primary cause
of the disease is that beyond certain stage in the evolution,
non-cell autonomous mechanisms leading to cell death
may overwhelm the potential benefits of gene- or phar-
macological therapies. Cell death may be due to the
release of proapoptotic signals in the photoreceptor envi-
ronment, or to the lack of survival factors normally pro-
duced by the living cells. The latter has been confirmed by
the discovery that rods produce factors that are necessary
for cone survival [49]. Thus, in typical RP, rods die
because they express a mutated gene, and cones, which do
not express the mutated gene, are secondarily degenerat-
ing because of the lack of rod factors. Therefore, the sup-
ply of rod factors in the retina would protect cones against
secondary degeneration.
• Neuroprotection using growth factors
Several growth factors, including ciliary neurotrophic fac-
tor (CNTF), glial-derived neurotrophic factor (GDNF),
cardiotrophin-1, brain-derived neurotrophic factor
(BDNF) and basic fibroblast growth factor (bFGF) have
some efficacy in animal models, that varies from one
model to another. Their short half-life requires their deliv-
ery in situ. Since iterative intravitreal injections are not rec-
ommended, several strategies like use of encapsulated
cells producing bFGF placed in the vitreous cavity [50]
and gene transfer of GDNF in resident cells [51] have been
tried. These factors, however, have side effects including
retinal neovascularization and cataract. For example,Orphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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CNTF allows an excellent preservation of retinal integrity
in several animal models, but it causes a decrease in the
ERG response of the retina by yet unknown toxic mecha-
nism [52]. Nevertheless, encapsulated cells releasing
CNTF of vitreous of patients with RP is currently under
Phase I clinical investigation [53].
• Neuroprotection using antiapoptotic factors
In animal models, gene transfer of anti-apoptotic bcl-2
slows down the photoreceptor cell death [54] as well as
the use of an inhibiting peptide of caspase-3 [55].
• Rod-derived cone viability factor
Léveillard et al. [56] identified a rod-derived cone viability
factor (RdCVF) that appears to be a truncated thioredoxin-
like protein which significantly delays cone death in the
rd1  mouse model of RP. Studies are ongoing to test
whether this factor will be efficient in other forms of RP.
Restoration of visual function
Beside therapies aimed at preserving visual function and
preventing cell death, one would like to find out ways of
restoring the visual function. This is a tremendous chal-
lenge since (as a general rule for neurons in the CNS)
human photoreceptors are not produced and do not
divide after birth, therefore, their loss is irreversible. In
addition, the loss of photoreceptors leads to a dramatic
remodeling of the retinal circuits which would probably
modify the visual information process if correct implanta-
tion of new photoreceptors was possible. Nevertheless,
numerous teams are now working to achieve visual resto-
ration either by photoreceptor replacement or by means
of artificial devices.
• Cell or tissue transplantation
Experiments have been tried to transplant retinal cells
from fetuses or adult retina in humans, and layers of pho-
toreceptors or even entire retina in animals models (rats
and rabbits). Generally, the survival of transplanted pho-
toreceptors is readily observed, but they do not properly
organize in the retina (forming rosettes) and lack, with
rare exceptions, functional synapses. Researchers are also
becoming interested by using stem cells, embryonic or
adult, from retina or from other tissues. Although very
interesting to study, these therapeutic approaches are still
far from realistic use in a near future.
Conversely to photoreceptors, it has been proven that the
RPE grafts rescue the photoreceptors in Royal College of
Surgeons (RCS) rat model, in which a mutation in c.Mertk
causes a retinal dystrophy by lack of outer segment phago-
cytosis of the RPE, and in rare cases of RP in humans
[57,58]. In RP due to RPE defects, RPE transplantation is
then theoretically possible, but one has to resolve the
immunogenic reaction against allogenic, wild type RPE.
• Retinal prosthesis
Microphotodiodes arrays that replace degenerated pho-
toreceptors or more sophisticated devices that capture
light and stimulate the retina, optic nerve or visual cortex
have been developed. Several clinical trials have essen-
tially demonstrated the tolerance of the implanted
devices. Today, they represent the basis for further studies
towards improvement of the future devices resolution.
Prognosis
Evaluation of the prognosis is not an easy task as the qual-
ity of vision is depending on several features such as
peripheral visual field, visual acuity and perception of
contrasts which may not change in concert. For example,
one patient with a long-evolved RP may feel fortunate
because of a relatively good visual acuity to 4/10, even if
his/her tiny visual field limited to 5° around the fixation
point does not allow autonomous walking outside, while
a younger patient, with a better visual field will feel unfor-
tunate with a visual acuity less than 1/10 due to macular
atrophy.
Few studies have addressed the question about the disease
prognosis, even though this is a very important concern
for patients. The rate of decline in visual performance is
depending on many parameters that include the gene and
type of mutations as well as other genetic and environ-
mental factors. It has been recently established that the
disease course in patients with pericentral RP is slower
that those with typical RP [59]. There are also several
clues, such as the Optical Coherence Tomography (OCT)
third high-reflectance band, which may help to predict
which patients are more likely to lose visual acuity with
the decline of the retinal thickness [60].
Overall, we clearly need to use standardized tests over
extended periods of time to precisely determine clinical
subgroups who will be relevant for clinical trials, in partic-
ular to appreciate the efficacy of treatments.
Unresolved questions
Cloned genes account for 40 to 54% of the autosomal
dominant cases, 61 to 89% of the X-linked cases, and
probably less than 1/3 of the autosomal recessive cases,
not taking into account all the sporadic cases (45% of all
RP cases). Therefore, it can be broadly estimated that half
the genes have yet to be discovered. It is anticipated that
modifier genes play important roles, in particular in
incomplete penetrance of autosomal dominant RP and in
sporadic cases. Those modifier genes, that could also be
used for therapeutic prospects, remain to be discovered.
The understanding of the role of the encoded proteins
often requires many years. Today, for a number of pro-
teins, substantial information about their function is
available, while some of them remain poorly known.Orphanet Journal of Rare Diseases 2006, 1:40 http://www.OJRD.com/content/1/1/40
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A challenging issue is the elucidation of the precise steps
leading from a gene mutation to photoreceptor degenera-
tion. Data from animal models and clinical studies sug-
gest that photoreceptors die by apoptosis at a linear rate
throughout life (named the one-hit hypothesis), implying
that they have a given probability to undergo apoptosis
that remains constant from early to late stages of the dis-
ease [61]. For certain genes or severe mutations, this prob-
ability will be high, while for others it will be lower. The
results of experimental and clinical studies clearly indicate
that the mechanisms of photoreceptor degeneration are
multiple. In all genetic forms of RP studied till now, data
are incomplete. In addition, it is likely that several apop-
totic pathways are involved in the photoreceptor loss,
sometimes concurrently, and this also needs to be care-
fully investigated. This knowledge is crucial to design ther-
apies. The efficacy of various potential treatments has to
be proven in large animal models and in humans. For
example, gene replacement therapy for RDS in mouse
improves photoreceptor ultrastructure, but there is no sig-
nificant effect on photoreceptor cell loss [62].
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